| Zynteglo |
125717 |
001 |
351(a) |
betibeglogene autotemcel |
For Injection |
Intravenous |
1.7-20 X 10^6CELL/ML |
Bag |
2022/08/17
|
Bluebird Bio Inc. |
Rx |
Licensed |
N/A |
N/A |
| Hadlima |
761059 |
004 |
351(k) Interchangeable |
adalimumab-bwwd |
Injection |
Subcutaneous |
40MG/0.4ML |
Autoinjector |
2022/08/15
|
Samsung Bioepis Co., Ltd. |
Rx |
Licensed |
adalimumab |
Humira |
| Hadlima |
761059 |
005 |
351(k) Interchangeable |
adalimumab-bwwd |
Injection |
Subcutaneous |
40MG/0.4ML |
Pre-Filled Syringe |
2022/08/15
|
Samsung Bioepis Co., Ltd. |
Rx |
Licensed |
adalimumab |
Humira |
| Rebinyn |
125611 |
004 |
351(a) |
Coagulation Factor IX (Recombinant), GlycoPEGylated |
For Injection |
Intravenous |
3000IU |
Single-Dose Vial |
2022/08/11
|
Novo Nordisk Inc. |
Rx |
Licensed |
N/A |
N/A |
| Cimerli |
761165 |
001 |
351(k) Interchangeable |
ranibizumab-eqrn |
Injection |
Intravitreal |
10MG/ML (0.5MG/0.05ML) |
Single-Dose Vial |
2022/08/02
|
Sandoz Inc. |
Rx |
Licensed |
ranibizumab |
Lucentis |
| Cimerli |
761165 |
002 |
351(k) Interchangeable |
ranibizumab-eqrn |
Injection |
Intravitreal |
6MG/ML (0.3MG/0.05ML) |
Single-Dose Vial |
2022/08/02
|
Sandoz Inc. |
Rx |
Licensed |
ranibizumab |
Lucentis |
| Ultomiris |
761108 |
004 |
351(a) |
ravulizumab-cwvz |
Injection |
Subcutaneous |
245MG/3.5ML (70MG/ML) |
Single-Dose Cartridge |
2022/06/22
|
Alexion Pharmaceuticals, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Hadlima |
761059 |
003 |
351(k) Interchangeable |
adalimumab-bwwd |
Injection |
Subcutaneous |
40MG/0.8ML |
Single-Dose Vial |
2022/06/17
|
Samsung Bioepis Co., Ltd. |
Rx |
Licensed |
adalimumab |
Humira |
| Skyrizi |
761105 |
005 |
351(a) |
risankizumab-rzaa |
Injection |
Subcutaneous |
360MG/2.4ML (150MG/ML) |
Single-Dose Cartridge |
2022/06/16
|
AbbVie Inc. |
Rx |
Licensed |
N/A |
N/A |
| Skyrizi |
761262 |
001 |
351(a) |
risankizumab-rzaa |
Injection |
Intravenous |
600MG/10ML (60MG/ML) |
Single-Dose Vial |
2022/06/16
|
AbbVie Inc. |
Rx |
Licensed |
N/A |
N/A |
| PRIORIX |
125748 |
001 |
351(a) |
Measles, Mumps and Rubella Vaccine Live |
For Injection |
Subcutaneous |
3.4, 4.2 and 3.3LOG10 |
Single-Dose Vial |
2022/06/03
|
GlaxoSmithKline Biologicals |
Rx |
Licensed |
N/A |
N/A |
| Beovu |
761125 |
002 |
351(a) |
brolucizumab-dbll |
Injection |
Intravitreal |
6MG/0.05ML |
Pre-Filled Syringe |
2022/05/27
|
Novartis Pharmaceuticals Corporation |
Rx |
Licensed |
N/A |
N/A |
| Fylnetra |
761084 |
001 |
351(k) Biosimilar |
pegfilgrastim-pbbk |
Injection |
Subcutaneous |
6MG/0.6ML |
Pre-Filled Syringe |
2022/05/26
|
Kashiv BioSciences, LLC |
Rx |
Licensed |
pegfilgrastim |
Neulasta |
| Sucraid |
020772 |
002 |
351(a) |
sacrosidase |
Solution For Oral |
Oral |
17,000IU/2ML (8,500IU/ML) |
|
2022/05/25
|
QOL Medical, LLC |
Rx |
Licensed |
N/A |
N/A |
| Alymsys |
761231 |
001 |
351(k) Biosimilar |
bevacizumab-maly |
Injection |
Intravenous |
100MG/4ML (25MG/ML) |
Single-Dose Vial |
2022/04/13
|
Amneal Pharmaceuticals LLC |
Rx |
Licensed |
bevacizumab |
Avastin |
| Alymsys |
761231 |
002 |
351(k) Biosimilar |
bevacizumab-maly |
Injection |
Intravenous |
400MG/16ML (25MG/ML) |
Single-Dose Vial |
2022/04/13
|
Amneal Pharmaceuticals LLC |
Rx |
Licensed |
bevacizumab |
Avastin |
| Hyrimoz |
761071 |
003 |
351(k) Interchangeable |
adalimumab-adaz |
Injection |
Subcutaneous |
10MG/0.2ML |
Pre-Filled Syringe |
2022/03/28
|
Sandoz Inc. |
Disc |
Licensed |
adalimumab |
Humira |
| Cyltezo |
761058 |
003 |
351(k) Interchangeable |
adalimumab-adbm |
Injection |
Subcutaneous |
10MG/0.2ML |
Pre-Filled Syringe |
2022/03/18
|
Boehringer Ingelheim Pharmaceuticals, Inc. |
Rx |
Licensed |
adalimumab |
Humira |
| Opdualag |
761234 |
001 |
351(a) |
nivolumab and relatlimab-rmbw |
Injection |
Intravenous |
240MG, 80MG/20ML (12MG, 4MG/ML) |
Single-Dose Vial |
2022/03/18
|
Bristol-Myers Squibb Company |
Rx |
Licensed |
N/A |
N/A |
| Carvykti |
125746 |
001 |
351(a) |
ciltacabtagene autoleucel |
For Injection |
Intravenous |
0.5 to 1.0x10^6 chimeric antigen receptor (CAR)-positive viable T cells per kg of body weight, with a maximum dose of 1x10^8 CAR-positive viable T cells in one infusion |
Bag |
2022/02/28
|
Janssen Biotech, Inc. |
Rx |
Licensed |
N/A |
N/A |